Control of fluoroquinolone resistance through successful regulation, Australia

dc.contributor.authorCheng, A.
dc.contributor.authorTurnidge, J.
dc.contributor.authorCollignon, P.
dc.contributor.authorLooke, D.
dc.contributor.authorBarton, M.
dc.contributor.authorGottlieb, T.
dc.date.issued2012
dc.description.abstractFluoroquinolone antimicrobial drugs are highly bioavailable, broad-spectrum agents with activity against gram-negative pathogens, especially those resistant to other classes of antimicrobial drugs. Australia has restricted the use of quinolones in humans through its national pharmaceutical subsidy scheme; and, through regulation, has not permitted the use of quinolones in food-producing animals. As a consequence, resistance to fluoroquinolones in the community has been slow to emerge and has remained at low levels in key pathogens, such as Escherichia coli. In contrast to policies in most other countries, this policy has successfully preserved the utility of this class of antimicrobial drugs for treatment of most infections.
dc.description.statementofresponsibilityAllen C. Cheng, John Turnidge, Peter Collignon, David Looke, Mary Barton, and Thomas Gottlieb
dc.identifier.citationEmerging Infectious Diseases, 2012; 18(9):1453-1460
dc.identifier.doi10.3201/eid1809.111515
dc.identifier.issn1080-6040
dc.identifier.issn1080-6059
dc.identifier.orcidTurnidge, J. [0000-0003-4240-5578]
dc.identifier.urihttp://hdl.handle.net/2440/73752
dc.language.isoen
dc.publisherCenter Disease Control
dc.rightsCopyright status unknown
dc.source.urihttps://doi.org/10.3201/eid1809.111515
dc.subjectAnimals
dc.subjectHumans
dc.subjectFluoroquinolones
dc.subjectAnti-Bacterial Agents
dc.subjectDrug Resistance, Bacterial
dc.subjectGovernment Regulation
dc.subjectDrug and Narcotic Control
dc.subjectAustralia
dc.subjectDrug Prescriptions
dc.titleControl of fluoroquinolone resistance through successful regulation, Australia
dc.typeJournal article
pubs.publication-statusPublished

Files